NeuroThera Labs, a subsidiary of SciSparc Ltd., is pursuing FDA Orphan Drug Designation for SCI-110, its cannabinoid-based drug candidate for adult Tourette Syndrome. This designation targets rare diseases affecting fewer than 200,000 people in the US and could enhance SCI-110's market profile if granted. SCI-110 is currently in Phase IIb clinical trials across the US, Germany, and Israel, showing promise in reducing tics and related symptoms. NeuroThera has also engaged RK Strategies to strengthen its US regulatory and public affairs efforts, aiming to support long-term market access and commercial success for SCI-110.
Snowflake reported strong Q2 2026 results with earnings per share of $0.62, beating estimates of $0.45, and revenue of $1.55 billion, surpassing the expected $1.48 billion. The company achieved a 35% year-over-year revenue increase, driven by its rol...
Several tech stocks including Pasqal, Credo, Palo Alto Networks (PANW), FuelCell Energy (FCEL), and MongoDB (MDB) saw significant declines on September 2, 2026. Pasqal dropped over 21% despite positive quantum computing progress, likely due to profit...
On September 2, 2026, several small-cap stocks and leveraged ETFs saw significant gains. bioAffinity Technologies surged 47.5% amid volatility and recent clinical updates, while Focus Universal rose 33.7% likely due to speculative trading. Swvl Holdi...
Galiano Gold Inc. stands out in the gold mining sector with a Return on Invested Capital (ROIC) of 24.38%, nearly double its Weighted Average Cost of Capital (WACC) of 12.23%. This strong capital efficiency indicates the company is creating significa...
Sunstone Hotel Investors reported strong Q2 2026 results, surpassing market expectations and raising its full-year guidance for the second quarter in a row. The company improved its financial health by reducing net debt plus preferred equity to EBITD...
